CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2004-09-02): Children with idiopathic arthritis respond to hepatitis B vaccine


Children with idiopathic arthritis respond to hepatitis B vaccine

Last Updated: 2004-09-02 13:42:55 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Hepatitis B vaccination can generate an adequate immune response in children with juvenile idiopathic arthritis (JIA) and this response is unaffected by immunosuppressive therapy, new research suggests.

These findings have important implications for developing countries where hepatitis B virus (HBV) infection is endemic, lead author Dr. Ozgur Kasapcopur and colleagues, from Istanbul University in Turkey, note.

Initially, researchers thought that hepatitis B vaccination might worsen chronic rheumatologic diseases in adults. However, it was later show that this was not the case and, in fact, an effective immune response was observed. Still, the matter has not been resolved in children.

To address this issue, Dr. Kasapcopur's team evaluated the safety and efficacy of hepatitis B vaccination in 39 children with JIA and in 41 healthy controls. All of the JIA patients were in remission and tested negative for hepatitis B surface antigen. The subjects received the vaccine at 0, 1, and 3 months or at 0, 1, and 6 months.

The researchers' findings appear in the Annals of the Rheumatic Diseases for September.

With the exception of one JIA patient, all of the subjects displayed an anti-HBV antibody response. Antibody levels were significantly lower in the JIA group than in controls, but were still considered adequate for protection. Treatment with methotrexate or prednisolone did not influence antibody levels in the JIA group.

The vaccination schedule used did not affect antibody levels in the control group. In contrast, in the JIA group, there was a trend toward a better response with the 0, 1, and 6-month schedule (p < 0.07).

Hepatitis B vaccination appeared safe in the JIA group with none of the subjects experiencing a disease flare-up or clinical deterioration linked to vaccination.

"Further studies are needed with larger numbers of patients to confirm these findings," the authors state.

Ann Rheum Dis 2004;63:1128-1130.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2017 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.